|
|
Global Biopharmaceutical Contract Manufacturing MarketsPublished by: Frost & Sullivan Published: Jan. 9, 2008 - 57 Pages Table of Contents
AbstractThis Frost & Sullivan research service titled Global Biopharmaceutical Contract Manufacturing Markets provides a comprehensive overview of trends of biopharmaceutical contract manufacturing organizations (CMOs), covering mammalian and microbial cell manufacturing segments. Microbial derived biopharmaceuticals are first generation products, which is typically less complex than mammalian cell derived products. The forecasts and information provided in this research has been newly developed from coverage of CMOs and is validated with key industry participants.This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Service program. With this program, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Council. Market Overview Existing First Generation Products Driving Growth Contract manufacturing of biopharmaceuticals has moved beyond being a function of "available capacity" and "cost" to being a strategic option offering flexibility, quicker time to market and lower scale up costs. Current demand is largely driven by first generation products - rh protein therapeutics and monoclonal antibodies (MAbs) targeted for cancer - the markets for most of which continue to witness double digit growth. A large number of first generation biopharmaceutical products are nearing maturity and major biopharmaceutical companies are likely to move these out to contract manufacturing organizations (CMOs) and focus on next-generation drugs, which could offer higher revenues and margins. Interestingly, the prospect of biogenerics or biosimilars is driving some "traditional" generic manufacturers to explore the possible investment into building biopharmaceutical capacity. Europe is currently leading the way in developing a pathway for the approval of biogenerics. "Biogenerics or biosimilars are likely to have a limited impact on biopharmaceutical capacity over the next 3 to 5 years as the regulatory pathway is yet to be established," notes the analyst of this research service. "However, upon market entry, biogenerics are likely to have a significant effect on pricing and cost structures of CMOs, and could drive demand for additional capacity." Mammalian Cell Manufacturing expected to Lead Growth Given the estimation that over two-thirds of biopharmaceuticals in development are mammalian cell derived, contract manufacturing for this segment is expected to grow at a much higher rate than microbial contract manufacturing. As the fast emerging market, mammalian cell manufacturing offers contract manufacturers the opportunity to gain greater share in the market through proprietary technology platforms and the opportunity for process improvement and streamlining. A significant share of mammalian cell manufacturing capacity still resides within the biopharmaceutical companies themselves and the potential for outsourcing of new products in development is significantly higher. CMOs have been effective in streamlining the manufacturing process and improving production efficiency. Overall, North America continues to remain the primary demand driver for biopharmaceutical contract manufacturing. The Asian impact on biopharmaceuticals is definitely accelerating and going forward there are likely to be a greater number of partnerships and investment being targeted at this region. "Capacity utilization, which witnessed a decline between 2003 and 2006, is beginning to rise resulting in higher revenues from existing capacity," says the analyst. "With biopharmaceutical funding beginning to rise again, smaller biopharmaceutical companies are also more likely to consider building up capacity. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||